(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/028548 A3

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61K 39/395* (2006.01)
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/075445

(22) International Filing Date:
25 August 2022 (25.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/237,033 25 August 2021 (25.08.2021) US

(71) Applicants: **SYSTIMMUNE, INC.** [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). **BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.** [CN/CN]; Building 1, 161 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(72) Inventors: **GOULET, Dennis R.**; 6788 138th Ave NE #626, Redmond, Washington 98052 (US). **KHALILI, Jahan**; 12635 NE 130th Way #A103, Kirkland, Washington 98034 (US). **RENSHAW, Blair**; 16210 SE 166th Ct, Renton, Washington 98058 (US). **MAK, Nga Sze Amanda**; 9752 Marine View Dr, Mukilteo, Washington 98275 (US). **ZHU, Hai**; 19316 31st DR SE, Bothell, Washington 98012 (US). **ZHU, Yi**; 8-24, Building 6, No. 6, Lidu Road, Wuhou District, Chengdu, Sichuan (CN).

(74) Agent: **HAN, Zhihua**; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
06 April 2023 (06.04.2023)

WO 2023/028548 A3

(54) Title: BISPECIFIC TETRAVALENT ANTIBODY TARGETING EGFR AND HER3

(57) Abstract: A bispecific antibody comprises two sets of heavy and light chains, wherein each set of the heavy chain and the light chain form a Fab region having a binding specificity to EGFR; the antibody and further comprises a scFv domain covalently linked to N -terminal of the heavy chain, N -terminal of the light chain, or C-terminal of the light chain, wherein the scFv domain has a binding specificity to HER3.